Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 726,619 shares of the biopharmaceutical company’s stock after purchasing an additional 9,840 shares during the period. Federated Hermes Inc.’s holdings in Vanda Pharmaceuticals were worth $3,481,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. SG Americas Securities LLC boosted its position in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 5,459 shares in the last quarter. Wells Fargo & Company MN raised its stake in Vanda Pharmaceuticals by 28.0% in the fourth quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 7,339 shares during the last quarter. Brandywine Global Investment Management LLC boosted its holdings in Vanda Pharmaceuticals by 13.9% in the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 4,820 shares in the last quarter. Verition Fund Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Vanda Pharmaceuticals by 8.8% during the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 4,449 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $4.13 on Friday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.85 and a fifty-two week high of $6.75. The firm has a market capitalization of $240.85 million, a PE ratio of -12.91 and a beta of 0.72. The stock’s 50-day simple moving average is $4.62 and its 200-day simple moving average is $4.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were purchased at an average cost of $4.46 per share, with a total value of $44,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired a total of 32,000 shares of company stock valued at $151,180 over the last 90 days. Insiders own 8.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on VNDA. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.